Amended Statement of Ownership (sc 13g/a)
February 12 2021 - 7:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Acorda Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00484M106
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
|
x Rule 13d-1(b)
|
|
|
|
o Rule 13d-1(c)
|
|
|
|
o Rule 13d-1(d)
|
|
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
|
1
|
|
NAME OF REPORTING PERSON
|
|
|
|
|
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
|
|
|
|
|
|
|
|
|
|
Symphony Asset Management, LLC 94-3252504
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) o
|
|
|
|
|
(b) o
|
|
|
|
N/A
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
|
|
|
|
Delaware - U.S.A.
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
|
0
|
|
|
|
|
6
|
SHARED VOTING POWER
|
|
|
|
|
|
0
|
|
|
|
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
|
|
0 (based upon conversion of bonds CUSIP 00484MAB2)
|
|
10
|
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|
|
|
|
|
|
|
|
N/A
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
|
|
|
|
|
|
|
0.00%
|
|
12
|
|
TYPE OF REPORTING PERSON*
|
|
|
|
|
|
|
|
IA
|
|
|
Item 1(a)
|
Name of Issuer:
|
|
|
|
|
|
|
|
Acorda Therapeutics, Inc.
|
|
|
|
|
|
|
Item 1(b)
|
Address of Issuer’s Principal Executive Offices:
|
|
|
|
420 Saw Mill River Road
|
|
|
|
Ardsley, NY 10502
|
|
|
|
United States
|
|
|
|
|
|
|
Item 2(a)
|
Name of Person Filing:
|
|
|
|
Symphony Asset Management, LLC
|
|
|
|
|
|
|
Item 2(b)
|
Address of the Principal Office or, if none, Residence:
|
|
|
|
555 California Street, Suite 3100
|
|
|
|
San Francisco, CA 94104
|
|
|
|
|
|
|
Item 2(c)
|
Citizenship:
|
|
|
|
California – U.S.A.
|
|
|
|
|
|
|
Item 2(d)
|
Title of Class of Securities:
|
|
|
|
Common Stock
|
|
|
|
|
|
|
Item 2(e)
|
CUSIP Number:
|
|
|
|
00484M106
|
|
|
|
|
|
|
Item 3
|
If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:
|
|
|
|
|
|
|
|
(e)
|
x
|
An investment advisor in accordance with section 240.13d-1(b)(1)(ii)(E)
|
|
|
|
|
|
|
Item 4
|
Ownership:
|
|
|
|
(a)
|
Amount Beneficially Owned:
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
(b)
|
Percent of Class:
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
(c)
|
Number of shares as to which such person has:
|
|
|
|
|
|
|
|
|
|
(i)
|
sole power to vote or direct the vote:
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
(ii)
|
shared power to vote or direct the vote:
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
(iii)
|
sole power to dispose or to direct the disposition of:
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
(iv)
|
shared power to dispose or to direct the disposition of:
|
|
|
|
|
0
|
|
|
|
|
|
|
Item 5
|
Ownership of Five Percent or Less of a Class:
|
|
|
|
|
|
|
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following x.
|
|
|
Item 6
|
Ownership of More than Five Percent on Behalf of Another Person:
|
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
|
|
|
|
|
|
Item 7
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
Item 8
|
Identification and Classification of Members of the Group:
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
Item 9
|
Notice of Dissolution of a Group:
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
Item 10
|
Certification:
|
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in
the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing
the control of the issuer of such securities and were were not acquired in connection with or as a participant in any transaction having
such purpose or effect.
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
Symphony Asset Management, LLC
|
|
|
|
|
|
By: /S/ Erik Mogavero
|
|
|
Name: Erik Mogavero
|
|
|
Title: Managing Director
|
|
|
Head of Affiliate Compliance
|
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024
